Arcturus Therapeutics (ARCT) Competitors $21.25 +1.86 (+9.59%) Closing price 04:00 PM EasternExtended Trading$21.32 +0.07 (+0.35%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. IDYA, BLTE, IBRX, ARQT, RXRX, MESO, IRON, AGIO, DNLI, and SRPTShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include IDEAYA Biosciences (IDYA), Belite Bio (BLTE), ImmunityBio (IBRX), Arcutis Biotherapeutics (ARQT), Recursion Pharmaceuticals (RXRX), Mesoblast (MESO), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Its Competitors IDEAYA Biosciences Belite Bio ImmunityBio Arcutis Biotherapeutics Recursion Pharmaceuticals Mesoblast Disc Medicine Agios Pharmaceuticals Denali Therapeutics Sarepta Therapeutics Arcturus Therapeutics (NASDAQ:ARCT) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Do analysts rate ARCT or IDYA? Arcturus Therapeutics currently has a consensus price target of $50.57, indicating a potential upside of 137.98%. IDEAYA Biosciences has a consensus price target of $43.36, indicating a potential upside of 60.17%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78IDEAYA Biosciences 1 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.72 Which has stronger valuation & earnings, ARCT or IDYA? Arcturus Therapeutics has higher revenue and earnings than IDEAYA Biosciences. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M3.79-$80.94M-$2.23-9.53IDEAYA Biosciences$7M338.92-$274.48M-$3.79-7.14 Is ARCT or IDYA more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -49.26%. Arcturus Therapeutics' return on equity of -24.87% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-49.26% -24.87% -17.75% IDEAYA Biosciences N/A -31.42%-29.45% Which has more risk & volatility, ARCT or IDYA? Arcturus Therapeutics has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Do insiders & institutionals believe in ARCT or IDYA? 94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 15.3% of Arcturus Therapeutics shares are held by insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor ARCT or IDYA? In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 5 articles in the media. Arcturus Therapeutics' average media sentiment score of 0.81 beat IDEAYA Biosciences' score of 0.46 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryArcturus Therapeutics beats IDEAYA Biosciences on 10 of the 15 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$577.15M$3.36B$6.02B$10.45BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-9.5322.0385.1227.23Price / Sales3.79470.42589.70134.52Price / CashN/A44.9825.7730.18Price / Book2.3910.4312.676.76Net Income-$80.94M-$52.58M$3.32B$276.50M7 Day Performance3.81%0.98%0.49%0.85%1 Month Performance22.69%14.77%9.41%8.16%1 Year Performance1.58%21.29%79.11%43.62% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.4873 of 5 stars$21.25+9.6%$50.57+138.0%-9.6%$577.15M$152.31M-9.53180High Trading VolumeIDYAIDEAYA Biosciences4.0988 of 5 stars$27.49-0.5%$43.36+57.7%-13.4%$2.42B$7M-7.2580Analyst DowngradeBLTEBelite Bio2.6545 of 5 stars$78.10+3.3%$96.00+22.9%+44.2%$2.41BN/A-50.3910IBRXImmunityBio2.7204 of 5 stars$2.53-0.4%$10.75+324.9%-32.1%$2.40B$14.74M-5.27590Positive NewsAnalyst ForecastGap DownARQTArcutis Biotherapeutics1.2418 of 5 stars$19.76-0.8%$19.80+0.2%+111.6%$2.39B$196.54M-26.35150Analyst ForecastRXRXRecursion Pharmaceuticals2.2832 of 5 stars$5.53+0.7%$7.25+31.1%-16.5%$2.38B$58.84M-3.11400Gap DownMESOMesoblast1.9421 of 5 stars$17.32-5.9%$24.00+38.6%+80.0%$2.36B$17.20M0.0080Gap DownIRONDisc Medicine2.4277 of 5 stars$69.28+2.2%$98.30+41.9%+50.7%$2.36BN/A-15.5030AGIOAgios Pharmaceuticals4.4909 of 5 stars$40.89+1.0%$56.00+37.0%-4.1%$2.35B$36.50M3.72390DNLIDenali Therapeutics4.3391 of 5 stars$15.22-1.3%$33.50+120.1%-46.5%$2.25BN/A-5.44430News CoverageGap DownSRPTSarepta Therapeutics4.6315 of 5 stars$23.26+2.7%$39.32+69.0%-82.4%$2.21B$1.90B-26.741,372Analyst ForecastGap Up Related Companies and Tools Related Companies IDEAYA Biosciences Alternatives Belite Bio Alternatives ImmunityBio Alternatives Arcutis Biotherapeutics Alternatives Recursion Pharmaceuticals Alternatives Mesoblast Alternatives Disc Medicine Alternatives Agios Pharmaceuticals Alternatives Denali Therapeutics Alternatives Sarepta Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
